ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables in Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma

Aditi Mulgaonkar, Roy Elias, Layton Woolford, Bing Guan, Kien Nham, Payal Kapur, Alana Christie, Vanina T. Tcheuyap, Nirmish Singla, I. Alex Bowman, Christina Stevens, Guiyang Hao, James Brugarolas, Xiankai Sun

Research output: Contribution to journalArticlepeer-review


Purpose: Immune checkpoint inhibitors (ICI) targeting the programmed cell death protein 1 and its ligand (PD-1/PD-L1) have transformed the treatment paradigm for metastatic renal cell carcinoma (RCC). However, response rates to ICIs as single agents or in combination vary widely and predictive biomarkers are lacking. Possibly related to the heterogeneity and dynamic nature of PD-L1 expression, tissue-based methods have shown limited value. Immuno–positron emission tomography (immunoPET) may enable noninvasive, comprehensive, and real-time PD-L1 detection. Herein, we systematically examined the performance of immunoPET for PD-L1 detection relative to IHC in an RCC patient-derived tumorgraft (TG) platform. Experimental Design: Eight independent RCC TGs with a wide range of PD-L1 expression (0%–85%) were evaluated by immunoPET. Uptake of 89Zr-labeled atezolizumab ([89Zr]Zr-DFO-ATZ) was compared with PD-L1 expression in tumors by IHC through double-blind analyses. Clinical outcomes of ICI-treated patients whose TGs were examined were analyzed to evaluate the clinical role of immunoPET in RCC. Results: ImmunoPET with [89Zr]Zr-DFO-ATZ (day 6/7 postinjection) revealed a statistically significant association with PDL1 IHC assays (P ¼ 0.0014; correlation rXY ¼ 0.78). Furthermore, immunoPET can be used to assess the heterogeneous distribution of PD-L1 expression. Finally, studies in the corresponding patients (n ¼ 4) suggest that PD-L1 signal may influence ICI responsiveness. Conclusions: ImmunoPET with [89Zr]Zr-DFO-ATZ may enable a thorough and dynamic assessment of PD-L1 across sites of disease. The power of immunoPET to predict ICI response in RCC is being explored in an ongoing clinical trial (NCT04006522).

Original languageEnglish (US)
Pages (from-to)4907-4916
Number of pages10
JournalClinical Cancer Research
Issue number22
StatePublished - Nov 15 2022
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables in Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this